瑞舒伐他汀对高脂血症患者脂蛋白(a)超敏C反应蛋白的影响

The Change of Lipoprotein( a) and High Senstive C - reactive Protein in Patients with Hyperlipidemia by Rosuvastatin Treatment

目的:观察瑞舒伐他汀对高脂血症患者血清脂蛋白(a)、血清超敏c反应蛋白的影响及血清脂蛋白(a)、血清超敏c反应蛋白与急性冠脉综合征之间的相关性。方法:收集100例高脂血症患者,随机分成瑞舒伐他汀组50例和立普妥组50例。用瑞舒伐他汀10mg,立普妥20mg,两种药物每日一次,每次分别为10-20mg,持续6周。观察治疗前后总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、超敏C-反应蛋白(hs-CRP)及血清脂蛋白(a)含量的改变。结果:瑞舒伐他汀组治疗后TC、TG、LDL-C、hs-CPR较治疗前明显降低(t=24.146,10.104,10.862,22.05,P<0.05);两组治疗后HDL-C含量较治疗前上升(t=7.448,P<0.05);各指标两组间比较有差异有统计学意义(P<0.05)。瑞舒伐他汀组治疗后血清脂蛋白(a)较治疗前明显降低(t=25.33,P<0.05),两组间比较有差异有统计学意义(P<0.05)。在急性冠脉综合征患者中,血清hs-CRP和LP(a)呈正相关(r=0.54,P<0.05)。结论:瑞舒伐他汀更有效地发挥抗炎及降低血脂功能,hs-CRP和LP(a)可能是预测冠状动脉病变的标志物。

Objective： To observe the effect of rosuvastatin on hyperlipidemia with serum lipoprotein （a ）, serum high sensitivity C-reactive protein and to investigate the correlation between acute coronary syn dromes（ACS） and serum lipoprotein（a）,serum high sensitivity C-reactive protein. Method： 100 cases with hyperhpidemia were randomly divided into rosuvastatin group （ n = 50 ） and lipitor （ n = 50 ）, Using rosu- vastafin 10 mg, Lipitor 20mg, once a day. Each time was 10-20mg for 6 weeks. The contents of total choles terol （ TC ）, triglyceride （ TG ）, low density lipoprotein （ LDL-C ）, high density lipoprotein （ HDL-C ） and high sensitive C-reactive protein （hs-CRP） before and after treatment were observed. Results： The contents of TC,TG,LDL,hs-CRP after treatment were significantly lower than that before treatment （t = 24. 146,10. 104,10.862,7. 448 ,P〈0.05 ） ;The content of HDL-C after treatment than before treatment to rosuvastafin group was increased （ t = 2.315,2. 226, P〈0. 05 ） ; the index between the two groups showed significant difference （ P〈0.05 ）. The contents of LP （ a ） after treatment was significantly lower than that before treatment （ t = 25.33, P〈0.05 ） ; the index between the two groups showed no difference （ P〉0.05 ）. After multi-variate regression analysis, there was correlation between serum hs-CRP and lipoprotein（ a）level and ACS（ r=0. 54, P〈0.05 ）. Conclusion： Rosuvastatin hase good effect in anti-inflammatory and lipid-lowering, hs-CRP and LP （ a ） may be marker of coronary artery disease.